CATEGORY: Press Release

The London Clinic is the UK’s most renowned independent, private hospital, established 1932. The London Spine Clinic is first specialist spinal unit established in England, 1997. The London Clinic will be Aclarion’s first customer in London.   Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and […]

Development of this program supports Aclarion’s commitment to lead with strong clinical evidence and engage the payer community through key opinion leader advocacy. Aclarion to participate in upcoming ISASS 2023 on  June 1-3, 2023 in San Francisco, CA where their health economics outcomes abstract will presented   Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, […]

Nicholas Theodore, MD, FACS, FAANS, is Director of Neurosurgical Spine Center, Johns Hopkins, and Professor of Neurosurgery, Orthopaedics and Biomedical Engineering CLARITY is a post-market, multi-site trial, that will further evaluate the role of Nociscan in the diagnosis and surgical treatment of chronic low back pain. CLARITY is targeted to begin in the second half […]

  Success rate at 2 years for discogenic low back pain surgeries was 85% for patients whose treatment strategy was consistent with Nociscan-identified discs, a 22 percentage point improvement over patients whose treatment strategy was inconsistent with Nociscan-identified discs (85% vs. 63%; p=0.07) Nociscan is the first augmented intelligence platform to measure pain biomarkers in […]

Marks the eighth advisor to growing KOL program to build strong body of clinical evidence and support US commercialization Aclarion to participate in upcoming SPINEWEEK 2023   Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location […]

NociscanTM is the first evidence-supported SaaS platform to objectively measure discogenic biomarkers for insight into pathological pain. Nociscan provides decision support to help bridge a major diagnostic void. Robert Eastlack, MD will speak to his real-world experience using Nociscan to effectively evaluate CLBP.   Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare […]

Director of Endoscopic Spine Surgery at the University of Miami Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that Gregory Basil, MD, Director of Endoscopic Spine Surgery at […]

Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that George Frey MD, Founder of the Colorado Comprehensive Spine Institute will advise the company as a key opinion leader […]

Broomfield, CO. In a recent publication of the Wall Street Transcript, Jeff Thramann, Aclarion’s Executive Director and Executive Chairman, was featured in an interview discussing the value and opportunity of the Nociscan solution in the chronic low back pain (cLBP) market. Read the full article here. Aclarion Wall Street Transcript Article

Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that Dr. Christopher Ames, Director of Spinal Deformity and Spine Tumor Surgery and Co-Director of the Combined High Risk Spine […]